BioMed Research International

BioMed Research International / 2019 / Article

Research Article | Open Access

Volume 2019 |Article ID 8301569 | 9 pages | https://doi.org/10.1155/2019/8301569

Phenothiazinium Dyes Are Active against Trypanosoma cruzi In Vitro

Academic Editor: Marija Mostarica-Stojković
Received01 Feb 2019
Revised10 May 2019
Accepted10 Jun 2019
Published04 Jul 2019

Abstract

Chagas disease is a tropical illness caused by the protozoan Trypanosoma cruzi. The disease affects populations of the Americas and has been spread to other continents due to the migration process. The disease is partially controlled by two drugs, Benznidazole and Nifurtimox. These molecules are active in the acute phase of the infection but are usually ineffective during the symptomatic chronic phase. Several research groups have developed novel candidates to control Chagas disease; however, no novel commercial formulation is available. In this article, we described the anti-T. cruzi effects of phenothiazinium dyes in amastigote and trypomastigote forms of the parasite. Methylene Blue, New Methylene Blue, Toluidine Blue O, and 1,9-Dimethyl Methylene Blue inhibited the parasite proliferation at nanomolar concentrations and also demonstrated low toxicity in host cells. Moreover, combinations of phenothiazinium dyes indicated a synergic pattern against amastigotes compared to the Benznidazole counterparts. Phenothiazinium dyes levels of reactive oxygen species (ROS) and decreased the mitochondrial potential in trypomastigotes, indicating the mechanism of action of the dyes in T. cruzi. Our article offers a basis for future strategies for the control of Chagas disease using low-cost formulations, an important point for endemic underdeveloped regions.

1. Introduction

Trypanosoma cruzi is the etiologic agent of the Chagas disease, endemic in the Americas. Chagas disease afflicts ~ 6 million to 7 million people and nowadays has spread to North America, Europe, Asia, and Oceania due to migration. The disease has two distinct phases; the acute phase is asymptomatic or causes unspecific symptoms. The chronic phase, when symptomatic, may lead to cardiac and/or digestive degeneration [1].

Despite the effort of several groups to develop novel therapies [2], there are only two commercial drugs for Chagas disease control, Benznidazole and Nifurtimox [3]. Moreover, several cases of treatment failure have been described [4], demanding new active and safe drugs. In this article, we investigated the anti-T. cruzi effect of phenothiazinium dyes, a low-cost family of drugs with potential against malaria [5]. Methylene Blue (MB), the most used phenothiazinium dye, has been applied against malaria since the XIX century, representing the first report of treatment with a synthetic molecule [6]. Due to the reversible side effects (green sclera and urine), MB was replaced by alternative antimalarial molecules, such as quinine, artemisinin, and chloroquine [7]. Nowadays MB has been revived for control of malaria, cancer, cyanide poisoning, and methaemoglobinaemia and recently in the treatment of patients with Alzheimer’s disease [8].

In this study, we evaluated the potential of the phenothiazinium dyes for the control of T. cruzi in vitro. We also determined several synergic formulations composed by phenothiazinium dyes and/or Benznidazole. ROS production and mitochondrial activity in treated cultures were assayed by flow cytometry, in order to investigate some aspects of the mechanism of action of phenothiazinium dyes in T. cruzi. The screening of low-cost compounds is a key factor for the control of the Chagas disease in endemic regions, most of them being in a delicate economic state.

2. Material and Methods

2.1. T. cruzi Culture

T. cruzi (Tulahuen strain) was maintained in cultures of LLCMK2 cells and cultivated in RMPI supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO2. The parasites used in proliferation and flow cytometry assays were genetically modified to express the enzyme β-galactosidase (T. cruzi-LacZ [9]). To illustrate the inhibition of parasite proliferation, a T. cruzi expressing GFP (G-GFP strain [10]) was used.

2.2. Compounds

Methylene Blue (MB), New Methylene Blue (NMB), Toluidine Blue O (TBO), and 1,9–Dimethyl Methylene Blue (DMMB) were purchased from Sigma-Aldrich and diluted in PBS at 5 mg/ml. Benznidazole (BZ) and Menadione (MN) was purchased from Sigma-Aldrich and diluted at 5 mg/ml in dimethyl sulfoxide (DMSO).

2.3. Amastigote Growth Inhibition Assay

LLCMK2 cells were distributed in 96-well plates (5×104 cells/ml) and infected with T. cruzi-LacZ at a multiplicity of infection (MOI) of 10:1 (5×105 cells/ml). The cultures were incubated for 48 h, 37°C, and 5% CO2 and washed with phosphate buffered saline (PBS). Serial dilutions of compounds (starting from 10 μM) in RPMI were added to the cultures in duplicate and incubated for 72 h, 37°C,and 5% CO2. For the drug combination assay, fractioned dilutions (2 × IC50, 1.6 × IC50, 1.3 × IC50, 0.7 × IC50, 0.5 × IC50, and 0.2 × IC50) of single and combined compounds [11] were added to the infected cultures and incubated under the same conditions. We considered 8 μM, 1 μM, 0.05 μM, 0.7 μM, and 0.04 μM as 2 × IC50 for BZ, MB, NMB, TBO, and DMMB, respectively. After incubation, the media were removed and followed by the reaction with chlorophenol red-β-D-galactopyranoside (CPRG) buffer (200 μM CPRG, 2% Trion X-100, and 50 mM MgCl2 in PBS) for 4 h, 37°C. The plates were read at 570 nm in ELISA reader (Synergy™ H1, Biotek). Three independent assays were performed.

2.4. Fluorescence Microscopy

LLCMK2 cells (2 × 103 cells per well) were cultivated in 96-well, black, flat-bottomed plates for 6 h, 37°C, and 5% CO2. The plate was washed with PBS and the cells were infected with T. cruzi (G-GFP strain) at a multiplicity of infection (MOI) of 5:1 (1×105 cells/ml). The cultures were incubated for 24 h, 37°C, 5% CO2, and the wells washed 3 times with PBS in order to remove noninternalized parasites. Subsequently, IC50 concentrations of MB, NMB, TBO, DMMB, and BZ were added to the cultures and the plates were incubated for 72 h, 37°C, and 5% CO2. Infected and nontreated and noninfected cells were used as negative controls and positive controls, respectively. After the incubation, the plates were fixed with 4% paraformaldehyde for 20 minutes, followed by washing with PBS. The nucleus of host cells was stained with 0.25 μM 4′,6-diamidine-2′-phenylindole dihydrochloride (DAPI) (Ex/Em = 340/488 nm) and the GFP T. cruzi parasites were detected by the green florescence (Ex/Em = 488/510 nm). The images were acquired in an Image Xpress Micro XLS Widefield High-Content Analysis System from Molecular Devices. The system also calculated the percentage of inhibition compared to the nontreated control. This was done using the number of intracellular amastigotes in twenty-five images obtained for each well.

2.5. Cytotoxicity

The cytotoxic effects of the phenothiazinium dyes in LLCMK2 cells was measured by Thiazolyl Blue Tetrazolium Bromide (MTT) assay, as described in [12]. A suspension of LLCMK2 cells (5 × 104/ml) in RPMI supplemented with 10% FBS was distributed in 96-well plates and cultivated (37°C, 5% CO2) to the confluence. The media were discarded and serial dilutions of the compounds were added (starting from 100 μM) in duplicate. The cultures were incubated for 72 h, 37°C, and 5% CO2. For the measurement of the cellular esterase activity, the media were carefully removed and an MTT solution (500 μg/ml MTT in PBS) was added. The reaction was performed for 4 h at 37°C, 5% CO2. After the reaction, the MTT solution was discarded and the formazan crystals solubilized with DMSO. The absorbance was measured in an ELISA reader (Synergy™ H1, Biotek) at 570 nm.

2.6. ROS Measurement and Evaluation of Mitochondrial Membrane Potential Status

LLCMK2 cells in 75 cm2 flasks were cultivated to confluence and were infected with 1 × 107 T. cruzi trypomastigotes. The cultures were cultivated for 6 days when free trypomastigotes were observed in the supernatant. The infected cells were centrifuged for 10 min, 3000 g, and washed with PBS and suspended in trypsin to separate cells and parasites. The cultures were distributed in 1.5 ml microtubes (~ 1 × 106 trypomastigotes/tube) and incubated with 4 × IC50 of compounds at 37°C, 5% CO2 for 2 h. Menadione (MN), a classic inducer of cellular oxidative stress [13], was used as the positive control of ROS production as previously described in [14]. After treatment, the cultures were centrifuged for 10 minutes, 3000 g, and washed with PBS and suspended in trypsin. The ROS measurement was performed after incubation with 5 μM 2,7–dichlorofluorescin diacetate (DCFDA) for 15 minutes at room temperature in the dark. Similarly, the mitochondrial membrane potential was determined after incubation with 5 μM JC-1 under the same conditions. JC-1 is a cationic dye that accumulates in active mitochondria. In low concentrations, the dye exhibits a green fluorescence. In polarized mitochondria, the dye forms J-aggregates, emitting red fluorescence. The cultures were washed with PBS and analyzed in a BD FACS-Canto (BD Biosciences) flow cytometer with the FACSDiva (BD) 6.1.3 software. Due to the size, host cells (infected and noninfected) and trypomastigotes were separately analyzed by flow cytometry [11]. The median of fluorescence of oxidized DCF and the populations with active mitochondria were measured with excitation/emission at 488 nm/529 nm and 488 nm/529 nm, respectively. The percentage of DCF fluorescence or cells with polarized mitochondria was calculated in relation to the respective nontreated controls.

2.7. Statistical Analysis

The percentages of proliferation and cytotoxicity were calculated using the mean absorbance of the compound-free control and the absorbance of each treatment. The IC50 and the combination index (CI) were achieved using Compusyn software (http://www.combosyn.com/) and the selective index (CC50/IC50) was also determined. From CI values, synergistic (CI < 1), and antagonistic (CI > 1) interactions were identified [15]. For oxidative stress and mitochondrial activity, data were analyzed by one-way ANOVA followed by a Dunnett’s post hoc test (compared to nontreated groups) on GraphPad 5.0 software.

3. Results and Discussion

3.1. Phenothiazinium Dyes Inhibit the Amastigote Proliferation at Low Concentrations

The phenothiazinium dyes inhibited the amastigote proliferation at low concentrations. The MB, NMB, TBO, and DMMB IC50 concentrations were lower compared to BZ (3.41 μM), reaching 0.44 μM, 0.09 μM, 0.27 μM, and 0.08 μM, respectively (Table 1). Moreover, a similar inhibition pattern between BZ and phenothiazinium dyes was observed using high-content screening analysis by amastigotes counting (Figure 1). At IC50 concentrations (Table 1) all tested compounds partially inhibited parasite proliferation (Figures 1(c), 1(d), 1(e), 1(f), 1(g), and 1(h)), compared to the nontreated control (Figure 1(b)). However, the phenothiazinium dyes demonstrated higher cytotoxicity (lower CC50) in relation to BZ (> 200 μM) wherein MB, NMB, TBO, and DMMB inhibited the host cell reductases at 16.82 μM, 4.19 μM, 7.93 μM, and 4.46 μM, respectively. Despite the relative higher host cell toxicity, the selective index (SI) was above 25, which is adequate compared to the index recommended for candidate drugs for Chagas disease control. In drug screening procedures against T. cruzi, an SI > 10 is recommended for candidates with potential for use in in vivo and clinical assays [16, 17]. Moreover, MB has been successfully applied against malaria and to treat methemoglobinemia with few cases of toxicity [18, 19], reinforcing its potential use as anti-T. cruzi compound in further assays.


CompoundMWμMμMSI

MB319.850.44 ± 0.1516.82 ± 1.1837.40
NMB347.910.09 ± 0.014.19 ± 1.3044.71
TBO305.830.27 ± 0.117.93 ± 5.2228.61
DMMB416.050.08 ± 0.024.46 ± 0.2351.26
BZ260.253.41 ± 0.38> 200> 58.65

3.2. Phenothiazinium Combinations Are Synergic against Amastigotes In Vitro

The combination of compounds has an important potential for the control of the Chagas disease. Several combinations of BZ with Itraconazole, E1224 (ravuconazole prodrug), and ketoconazole have demonstrated improved anti-T. cruzi pattern compared to the single treatments [2022]. The main aim of combinations with BZ is the decrease of dosages allied to the alleviation of side effects, which allow longer-term treatments. However, the combinations of phenothiazinium dyes with BZ resulted in an antagonist effect (CI > 1), despite the elevation of the parasite inhibition, mostly at lower concentrations (Figures 2(a), 2(b), 2(c), 2(d), and Table 2). However, the combinations among phenothiazinium dyes were synergic against amastigotes (except MB + DMMB), improving the parasite inhibition in all concentrations analyzed (Figures 2(e), 2(f), 2(g), 2(h), 2(i), and 2(j)). The CI of MB + NMB, MB + TBO, MB + DMMB, NMB + TBO, NMB + DMMB, and TBO + DMMB were 0.90, 0.89, 1.05, 0.74, 0.80, and 0.42, respectively (Table 2). The CI values probably indicate some differences in mechanisms of action among the phenothiazinium dyes. For example, the combinations containing TBO demonstrated the lowest CI values, probably due to low structure similarity with other dyes. In contrast, MB and DMMB are structurally similar, which reflected in an antagonist pattern when combined (Table 2). However, TBO demonstrated a high IC50 (compared to NMB or DMMB), which may affect negatively further in vivo treatments. Therefore, a wide and complex strategy for in vivo procedures is demanded, once there are multiple combinations and treatment regimens (acute, chronic, and pregnant models) to test.


Combination (compound 1 + 2)   
(compound 1/μM)
   
(compound 2/μM)
   
(combination compound 1/μM)
   
(combination compound 2/μM)
CI

BZ + MB3.3150.4772.2620.2911.29
BZ + NMB2.9370.1002.0910.0561.26
BZ + TBO3.0240.3802.2590.1781.40
BZ + DMMB3.0150.0781.9430.0501.28
MB + NMB0.5600.1120.2470.0510.90
MB + TBO0.5880.3220.2500.1500.89
MB + DMMB0.3910.0950.2230.0441.05
NMB + TBO0.1220.3220.0420.1260.74
NMB + DMMB0.1010.0710.0340.0330.80
TBO + DMMB0.3810.0800.0630.0200.42

3.3. Phenothiazinium Dyes Increase ROS in Treated Cells and Trypomastigotes

The literature is contradictory regarding the role of ROS produced by the host cell during T. cruzi infection. Several studies have implicated the host cell respiratory burst in controlling the infection [23, 24]. Others have reported a positive correlation between ROS production by the host and parasite proliferation [25, 26]. Also, when a sublethal hydrogen peroxide concentration was added to a T. cruzi infected culture, parasite proliferation increased [27]. Our results show increased ROS production in T. cruzi infected cells (untreated) when compared to noninfected cells (Figure 3(a)), corroborating an effect also observed for proliferating bacteria [28], fungi [29], viruses [30, 31], and Leishmania [32]. Despite the efficient antioxidant machinery [33], we observed increased ROS production in T. cruzi trypomastigotes after treatment with phenothiazinium dyes (Figure 3(b)). This effect was similar to the one observed for MN a classic inducer of oxidative stress [13]. On the other hand, no ROS production was detected in trypomastigotes treated with BZ. Although BZ induces the production of free radicals and electrophilic metabolites after the reduction of its nitro group, no ROS is produced in treated parasites [34]. We have observed that treatment with phenothiazinium dyes (and to a lesser extent BZ and MN) increased ROS production in noninfected cells (Figure 3(b)). In contrast, treating T. cruzi infected cells with phenothiazinium dyes decreased ROS production (Figure 3(b)). Indeed, Methylene Blue scavenges ROS in several biological models such as skin and HT-22 cells, elevating oxygen consumption and mitochondrial activity [3537]. Because T. cruzi proliferation is stimulated by ROS production [27], we speculate that scavenging of such ROS by phenothiazinium dyes impairs parasite proliferation. However, for the complete elucidation of the roles of phenothiazinium dyes in ROS scavenging, complementary assays will be required in further studies. As an example, the ability of phenothiazinium dyes to scavenge ROS may be compared to that of Trolox (6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid), a well-established ROS scavenger [38, 39].

3.4. Mitochondria of Trypomastigotes Are Sensitive to Phenothiazinium Dyes

All noninfected and infected LLCMK2 cells are positive to JC-1 accumulation, indicating the presence of active mitochondria. However, 22% of trypomastigotes were negative to mitochondrial polarization (Figure 4(a)). Moreover, phenothiazinium dyes decreased mitochondrial membrane potential in trypomastigotes, whereas the infected and noninfected cells were unaffected by incubation with the compounds (Figure 4(b)). Also, BZ and MN displayed distinct effects on the mitochondrial membrane potential of trypomastigotes. The former did not affect mitochondria whereas the latter reduced the membrane potential (Figure 4(b)). It was previously observed that BZ elevates free radical production and causes DNA damage without affecting mitochondria [40]. The effect of phenothiazinium dyes on trypomastigotes was similar to that observed for MN (Figure 4(b)), a classic mitochondrial inhibitor [41]. Thus, the increment of ROS observed in trypomastigotes under treatment with dyes may be a consequence of mitochondrial depolarization. Moreover, decreased mitochondrial activity may be also related to the ROS impairment production in infected cells treated with phenothiazinium dyes. Drugs that alter the mitochondrial activity usually lead to loss of parasite ATP production and induction of apoptosis [42]. For example, MB improves mitochondrial respiration in cells [35, 43], decreasing ROS in cardiac tissue from diabetic rats [44].

We have observed that active and synergic combinations of phenothiazinium dyes are effective in killing T. cruzi. Our results also indicate the potential of phenothiazinium dyes as candidates for the control of T. cruzi. We speculate that phenothiazinium dyes scavenge ROS during T. cruzi infection thus reducing parasite proliferation. However, future assays will be necessary to elucidate the mechanism. Furthermore, the induction of apoptosis by disruption of mitochondrial polarity should also be considered as a potential mechanism operating in conjunction with the ROS scavenging by phenothiazinium dyes. The present article opens the perspective for the development of low-cost and active anti-T. cruzi molecules, pivotal characteristics for the control of Chagas disease in low-middle-income endemic regions.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This work was developed within the framework of National Institute of Science and Technology of Pharmaceutical Nanotechnology (INCT-Nanofarma), which is supported by “Fundação de Amparo à Pesquisa do Estado de São Paulo” (Fapesp, Brazil, grant #14/50928-2) and “Conselho Nacional de Pesquisa” (CNPq, Brazil, grant #465687/2014-8). The authors also would like to thank CAPES for the Doctoral fellowship to GBP and Fabiana Rosseto de Morais (FCFRP-USP) for the technical assistance with the flow cytometry.

References

  1. World Health Organization, Chagas Disease (American Trypanosomiasis), 2018, World Health Organization website, http://www.who.int/mediacentre/factsheets/fs340/en/.
  2. C. B. Moraes and C. H. Franco, “Novel drug discovery for Chagas disease,” Expert Opinion on Drug Discovery, vol. 11, no. 5, pp. 447–455, 2016. View at: Publisher Site | Google Scholar
  3. F. S. Buckner, “Experimental chemotherapy and approaches to drug discovery for trypanosoma cruzi infection,” Advances in Parasitology, vol. 75, pp. 89–119, 2011. View at: Publisher Site | Google Scholar
  4. M. Campos, L. Leon, M. Taylor, and J. M. Kelly, “Benznidazole-resistance in Trypanosoma cruzi: evidence that distinct mechanisms can act in concert,” Molecular and Biochemical Parasitology, vol. 193, no. 1, pp. 17–19, 2014. View at: Google Scholar
  5. R. H. Schirmer, H. Adler, M. Pickhardt, and E. Mandelkow, “Lest we forget you--methylene blue,” in Neurobiology of Aging, pp. 2325 e7–2325 e16, Elsevier Inc, Atlanta, GA, USA, 2011. View at: Google Scholar
  6. P. Guttmann and P. Ehrlich, “Ueber die wirkung des methylenblau bei malaria,” Berliner klinische, Wochenschrift, vol. 28, no. 891, pp. 953–956, 1891. View at: Google Scholar
  7. P. R. Ginimuge and S. D. Jyothi, “Methylene blue: revisited,” Journal of Anaesthesiology Clinical Pharmacology, vol. 26, no. 4, pp. 517–20, 2010. View at: Google Scholar
  8. R. Suwanarusk, B. Russell, A. Ong et al., “Methylene blue inhibits the asexual development of vivax malaria parasites from a region of increasing chloroquine resistance,” Journal of Antimicrobial Chemotherapy, vol. 70, no. 1, pp. 124–129, 2015. View at: Publisher Site | Google Scholar
  9. F. S. Buckner, C. L. M. J. Verlinde, A. C. La Flamme, and W. C. Van Voorhis, “Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing β-galactosidase,” Antimicrobial Agents and Chemotherapy, vol. 40, no. 11, pp. 2592–2597, 1996. View at: Publisher Site | Google Scholar
  10. B. L. Ferreira, C. M. Orikaza, E. M. Cordero, and R. A. Mortara, “Trypanosoma cruzi: single cell live imaging inside infected tissues,” Cellular Microbiology, vol. 18, no. 6, pp. 779–783, 2016. View at: Publisher Site | Google Scholar
  11. L. M. Pereira, G. de Luca, N. D. L. M. Abichabki, C. M. Bronzon da Costa, and A. P. Yatsuda, “Synergic in vitro combinations of artemisinin, pyrimethamine and methylene blue against Neospora caninum,” Veterinary Parasitology, vol. 249, pp. 92–97, 2018. View at: Publisher Site | Google Scholar
  12. T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983. View at: Publisher Site | Google Scholar
  13. G. Bellomo, F. Mirabelli, M. Vairetti, F. Iosi, and W. Malorni, “Cytoskeleton as a target in menadione-induced oxidative stress in cultured mammalian cells. I. Biochemical and immunocytochemical features,” Journal of Cellular Physiology, vol. 143, no. 1, pp. 118–128, 1990. View at: Publisher Site | Google Scholar
  14. M. V. Providello, Z. A. Carneiro, G. B. Portapilla et al., “Benefits of ascorbic acid in association with low-dose benznidazole in treatment of chagas disease,” Antimicrobial Agents and Chemotherapy, vol. 62, no. 9, 2018. View at: Google Scholar
  15. T. Chou and P. Talalay, “Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors,” Advances in Enzyme Regulation, vol. 22, pp. 27–55, 1984. View at: Publisher Site | Google Scholar
  16. J. Alonso-Padilla and A. Rodríguez, “High throughput screening for anti–trypanosoma cruzi drug discovery,” PLOS Neglected Tropical Diseases, vol. 8, no. 12, p. e3259, 2014. View at: Publisher Site | Google Scholar
  17. M. L. Sykes and V. M. Avery, “Development and application of a sensitive, phenotypic, high-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotes,” International Journal for Parasitology: Drugs and Drug Resistance, vol. 5, no. 3, pp. 215–228, 2015. View at: Publisher Site | Google Scholar
  18. J. Clifton II and J. B. Leikin, “Methylene blue,” American Journal of Therapeutics, vol. 10, no. 4, pp. 289–291, 2003. View at: Publisher Site | Google Scholar
  19. G. Lu, M. Nagbanshi, N. Goldau et al., “Efficacy and safety of methylene blue in the treatment of malaria: A systematic review,” BMC Medicine, vol. 16, no. 1, p. 59, 2018. View at: Google Scholar
  20. T. A. F. Martins, L. D. F. Diniz, A. L. Mazzeti et al., “Benznidazole/itraconazole combination treatment enhances anti-Trypanosoma cruzi activity in experimental Chagas disease,” PLoS ONE, vol. 10, no. 6, Article ID e0128707, 2015. View at: Google Scholar
  21. L. F. Diniz, A. L. Mazzeti, I. S. Caldas, I. Ribeiro, and M. T. Bahia, “Outcome of E1224-Benznidazole combination treatment for infection with a multidrug-resistant trypanosoma cruzi strain in mice,” Antimicrobial Agents and Chemotherapy, vol. 62, no. 6, 2018. View at: Google Scholar
  22. M. S. S. Araújo, O. A. Martins-Filho, M. E. S. Pereira, and Z. Brener, “A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease,” Journal of Antimicrobial Chemotherapy, vol. 45, no. 6, pp. 819–824, 2000. View at: Publisher Site | Google Scholar
  23. M. N. Alvarez, G. Peluffo, L. Piacenza, and R. Radi, “Intraphagosomal peroxynitrite as a macrophage-derived cytotoxin against internalized Trypanosoma cruzi: Consequences for oxidative killing and role of microbial peroxiredoxins in infectivity,” The Journal of Biological Chemistry, vol. 286, no. 8, pp. 6627–6640, 2011. View at: Publisher Site | Google Scholar
  24. L. Piacenza, M. N. Alvarez, G. Peluffo, and R. Radi, “Fighting the oxidative assault: the Trypanosoma cruzi journey to infection,” Current Opinion in Microbiology, vol. 12, no. 4, pp. 415–421, 2009. View at: Publisher Site | Google Scholar
  25. C. N. Paiva and M. T. Bozza, “Are reactive oxygen species always detrimental to pathogens?” Antioxidants & Redox Signaling, vol. 20, no. 6, pp. 1000–1037, 2014. View at: Publisher Site | Google Scholar
  26. C. N. Paiva, E. Medei, and M. T. Bozza, “ROS and Trypanosoma cruzi: fuel to infection, poison to the heart,” PLoS Pathogens, vol. 14, no. 4, Article ID e1006928, 2018. View at: Google Scholar
  27. J. K. Finzi, C. W. M. Chiavegatto, K. F. Corat et al., “Trypanosoma cruzi response to the oxidative stress generated by hydrogen peroxide,” Molecular and Biochemical Parasitology, vol. 133, no. 1, pp. 37–43, 2004. View at: Publisher Site | Google Scholar
  28. J.-Y. Jung, R. Madan-Lala, M. Georgieva et al., “The intracellular environment of human macrophages that produce nitric oxide promotes growth of mycobacteria,” Infection and Immunity, vol. 81, no. 9, pp. 3198–3209, 2013. View at: Publisher Site | Google Scholar
  29. C. Jiménez-López, J. R. Collette, K. M. Brothers et al., “Candida albicans induces arginine biosynthetic genes in response to host-derived reactive oxygen species,” Eukaryotic Cell, vol. 12, no. 1, pp. 91–100, 2013. View at: Publisher Site | Google Scholar
  30. A. Fraternale, M. F. Paoletti, A. Casabianca et al., “GSH and analogs in antiviral therapy,” Molecular Aspects of Medicine, vol. 30, no. 1-2, pp. 99–110, 2009. View at: Publisher Site | Google Scholar
  31. R. Vlahos, J. Stambas, S. Bozinovski, B. R. S. Broughton, G. R. Drummond, and S. Selemidis, “Inhibition of Nox2 oxidase activity ameliorates influenza a virus-induced lung inflammation,” PLoS Pathogens, vol. 7, no. 2, Article ID e1001271, 2011. View at: Google Scholar
  32. B. Mittra, M. Cortez, A. Haydock, G. Ramasamy, P. J. Myler, and N. W. Andrews, “Iron uptake controls the generation of leishmania infective forms through regulation of ROS levels,” The Journal of Experimental Medicine, vol. 210, no. 2, pp. 401–416, 2013. View at: Publisher Site | Google Scholar
  33. G. R. Goes, P. S. Rocha, A. R. Diniz et al., “Trypanosoma cruzi needs a signal provided by reactive oxygen species to infect macrophages,” PLOS Neglected Tropical Diseases, vol. 10, no. 4, Article ID e0004555, 2016. View at: Publisher Site | Google Scholar
  34. S. R. Wilkinson, M. C. Taylor, D. Horn, J. M. Kelly, and I. Cheeseman, “A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 105, no. 13, pp. 5022–5027, 2008. View at: Publisher Site | Google Scholar
  35. Z. M. Xiong, M. O’Donovan, L. Sun, J. Y. Choi, M. Ren, and K. Cao, “Anti-aging potentials of methylene blue for human skin longevity,” Scientific Reports, vol. 7, no. 1, Article ID 2475, 2017. View at: Publisher Site | Google Scholar
  36. E. Poteet, A. Winters, L.-J. Yan et al., “Neuroprotective actions of methylene blue and its derivatives,” PLoS ONE, vol. 7, no. 10, article e48279, 2012. View at: Publisher Site | Google Scholar
  37. Y. Wen, W. Li, E. C. Poteet et al., “Alternative mitochondrial electron transfer as a novel strategy for neuroprotection,” The Journal of Biological Chemistry, vol. 286, no. 18, pp. 16504–16515, 2011. View at: Publisher Site | Google Scholar
  38. E. M. Messier, K. Bahmed, R. M. Tuder, H. W. Chu, R. P. Bowler, and B. Kosmider, “Trolox contributes to Nrf2-mediated protection of human and murine primary alveolar type II cells from injury by cigarette smoke,” Cell Death & Disease, vol. 4, no. 4, article 573, 2013. View at: Publisher Site | Google Scholar
  39. D. A. Mickle and R. D. Weisel, “Future directions of vitamin E and its analogues in minimizing myocardial ischemia-reperfusion injury,” Canadian Journal of Cardiology, vol. 9, no. 1, pp. 89–93, 1993. View at: Google Scholar
  40. R. Andreo, L. O. Regasini, M. S. Petronio et al., “Toxicity and loss of mitochondrial membrane potential induced by alkyl gallates in Trypanosoma cruzi,” International Scholarly Research Notices, vol. 2015, Article ID 924670, 7 pages, 2015. View at: Publisher Site | Google Scholar
  41. G. Loor, J. Kondapalli, J. M. Schriewer, N. S. Chandel, T. L. Vanden Hoek, and P. T. Schumacker, “Menadione triggers cell death through ROS-dependent mechanisms involving PARP activation without requiring apoptosis,” Free Radical Biology & Medicine, vol. 49, no. 12, pp. 1925–1936, 2010. View at: Publisher Site | Google Scholar
  42. L. A. Cortes, L. Castro, B. Pesce et al., “Novel gallate triphenylphosphonium derivatives with potent antichagasic activity,” PLoS ONE, vol. 10, no. 8, Article ID e0136852, 2015. View at: Google Scholar
  43. Z.-M. Xiong, J. Y. Choi, K. Wang et al., “Methylene blue alleviates nuclear and mitochondrial abnormalities in progeria,” Aging Cell, vol. 15, no. 2, pp. 279–290, 2016. View at: Publisher Site | Google Scholar
  44. O. M. Duicu, A. Privistirescu, A. Wolf et al., “Methylene blue improves mitochondrial respiration and decreases oxidative stress in a substrate-dependent manner in diabetic rat hearts,” Canadian Journal of Physiology and Pharmacology, vol. 95, no. 11, pp. 1376–1382, 2017. View at: Publisher Site | Google Scholar

Copyright © 2019 Gisele Bulhões Portapilla et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

523 Views | 254 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.